ABOS

Conviction 61HealthcareScan · Mon, Aug 10, 2026

ABOS$2.43-0.41%

ResistanceSupportVol 14Insider sell

Vol MA14 396.64K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Acumen Pharmaceuticals, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.acumenpharm.com ↗

Price2.43

Change-0.41%

Gap+0.00%

Rel volume3.77×

Avg volume409.91K

Avg $ vol931.19K

SMA 202.24

SMA 502.36

SMA 2002.36

Price vs 50+3.03%

Price vs 200+3.07%

MA stackbullish

50/200 cross—

Supertrenddown · 2.60

RSI (14)56

MACD hist0.03

MACD crossbull · 3d

Stoch %K / %D96 / 86

ADX (14)17

+DI / −DI28 / 16

RSI divergenceBullish

MACD divergenceBullish

ATR %+5.80%

ADR %6.18%

52w high3.37

52w low1.23

From 52w high-27.89%

Above 52w low+97.56%

New 52w highNo

SqueezeOff

Bollinger width18.83%

%B0.95

Donchian pos51.52%

Donchian high2.75

Donchian low2.09

AVWAP (52w high)2.62

vs AVWAP high-7.21%

AVWAP (52w low)2.40

vs AVWAP low+1.11%

OBV trendDown

Chaikin MF (20)-0.04

Today vs 20d3.77×

Avg vol (14d)396.64K

Avg vol (20d)409.91K

Avg $ vol (20d)931.19K

Market cap—

RS 3m (vs SPY)-6.91%

RS 6m (vs SPY)-5.67%

RS line new highNo

Trend template4/8

Technical rank44.1

1 week+11.47%

1 month-7.60%

3 months-5.08%

6 months+1.25%

1 year+71.13%

YTD+20.30%

P/E-1.45

P/B2.01

P/S—

P/FCF-1.52

EPS-2.00

Div yield—

ROE-138.71%

ROA-90.80%

Debt/Eq0.35

Current4.55

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-18.57%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value154.76M

Revenue—

Net income-20.74M

Gross profit—

Free cash flow-115.63M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out72.23M

Employees61

ListedThu, Jul 1, 2021

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeB

Conviction61 / 100

Pattern quality—

Tech rank44.1 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance2.83

Support2.10

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ABOS

All disclosures →

No recent disclosed trades by Congress in ABOS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ABOS · 4 buys · 6 sells

Insider	Side	Shares	Value	Traded	Filed
Porter Derrell Director · Stock Option (right to buy) · 2026-06-17	Exercise	13.04K	—	2026-06-17	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-17	Exercise	13.04K	$14K	2026-06-17	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-17	Sell	13.04K	$30K	2026-06-17	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-16	Sell	12.8K	$30K	2026-06-16	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-15	Exercise	6.46K	$7K	2026-06-15	2026-06-17
Porter Derrell Director · Stock Option (right to buy) · 2026-06-15	Exercise	6.46K	—	2026-06-15	2026-06-17
Porter Derrell Director · Common Stock · 2026-06-15	Sell	6.46K	$15K	2026-06-15	2026-06-17
Fountain Nathan B Director · Common Stock · 2026-06-09	Sell	6.4K	$14K	2026-06-09	2026-06-10
Porter Derrell Director · Stock Option (right to buy) · 2026-06-03	Grant	53.25K	$0	2026-06-03	2026-06-05
Fountain Nathan B Director · Stock Option (right to buy) · 2026-06-03	Grant	53.25K	$0	2026-06-03	2026-06-05

SEC filings

EDGAR filings in ABOS · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.